Bacterial Lysate

Phase 3Small molecule

FFondazione Policlinico Universitario Campus Bio-Medico

Bacterial Lysate is one of 26 small molecule programs targeting Respiratory Infections. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory InfectionsActive, not recruiting

AsthmaActive, not recruiting

Respiratory InfectionsPhase 3

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Bacterial Lysate

FFondazione Policlinico Universitario Campus Bio-Medico

Phase 3

1 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

Atrovent

2 10

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Respiratory Infections2 trials

OM 85 to Prevent Respiratory Infections in Older At Risk Patients

Recruiting·—·Phase 4·NCT06655272·360 enrolled

OM 85 to Prevent Respiratory Infections in Older At Risk Patients

Active, not recruiting·FFondazione Policlinico Universitario Campus Bio-Medico·Phase 4·NCT07178002·360 enrolled

Asthma1 trial

Bacterial Lysate In Preventing Asthma

Active, not recruiting·QQueen Mary University of London·Phase 2·NCT05064631·173 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Bacterial Lysate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bacterial Lysate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bacterial Lysate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione Policlinico Universitario Campus Bio-Medico company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFondazione Policlinico Universitario Campus Bio-Medico

Bacterial Lysate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Respiratory Infections2 trials

Asthma1 trial

References

Drug Info

Quick Facts

Related News